Postdoc, at Ohio State University, Columbus, United States.
Dr. Pankaj Kumar is a Postdoctoral Research Scholar at the Ohio State University, specializing in molecular and cancer biology. With a passion for studying the DNA-damage response and multidrug resistance in cancer, his research explores the molecular mechanisms driving cancer metastasis, immunotherapy, and stem cell biology. Dr. Kumar holds a Ph.D. from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, where he explored the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. His work spans the fields of cancer biology, hepatocellular carcinoma, and lupus nephritis. His notable contributions to cancer research and immunology have earned him multiple prestigious awards and grants. 🧬🌍
Profile
ORCID
Education
Dr. Pankaj Kumar’s academic journey reflects a solid foundation in molecular and cancer biology. He earned his Ph.D. (2014-2021) in Molecular and Cancer Biology from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India, where his thesis focused on the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. Prior to this, Dr. Kumar completed his M.S. in Biotechnology (2011-2013) from Babasaheb Bhimrao Ambedkar University (BBAU), Lucknow, India. His undergraduate education began at Chhatrapati Shahu Ji Maharaj University (CSJMU), Kanpur, India, where he received his B.S. in Biotechnology (2008-2011). His robust academic background laid the foundation for his deep dive into cancer biology, drug resistance, and immunology. 🎓📚
Experience
Dr. Pankaj Kumar’s research experience spans across various prestigious institutions. Since February 2021, he has been a Postdoctoral Research Scholar at Ohio State University, Columbus, USA, focusing on cancer biology and immunotherapy. Before this, from August 2014 to October 2021, he was a Research Fellow (Ph.D. Scholar) at CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, working under Dr. A. S. Sreedhar’s group. His expertise includes molecular pathways, tumor metastasis, and cancer immunotherapy. His research on drug resistance mechanisms has made significant contributions to cancer treatment advancements, making him a valuable asset to the field of molecular biology and cancer research. 🧪🔬
Research Interests
Dr. Kumar’s research spans multiple areas of cancer biology and immunotherapy, with a primary focus on the DNA-damage response, tumor metastasis, and multidrug resistance in cancer. His interests include the molecular basis of cancer progression, cancer immunotherapy, and stem cell biology. Additionally, he has explored the epithelial-to-mesenchymal transition (EMT), lupus nephritis, hepatocellular carcinoma, nonalcoholic fatty liver diseases (NAFLD), and non-alcoholic steatohepatitis (NASH). Dr. Kumar’s dedication to understanding cancer resistance mechanisms offers crucial insights into the development of new therapeutic approaches for treating aggressive and drug-resistant cancers. 🔬🧠
Awards
Dr. Pankaj Kumar has received several prestigious awards throughout his career. In 2019, he was awarded the Keystone Symposia Travel Award to attend the “Cancer Stem Cells” symposium in Hong Kong. He also received the Carl Storm International Diversity Fellowship from the Gordon Research Conference in 2018, which enabled him to attend the “GRC-Drug Resistance” event at Bryant University, USA. In addition, he was granted an International Travel Award from the Indian Council of Medical Research (ICMR) in 2018. His academic accolades include securing the CSIR-NET Junior/Senior Research Fellowship in 2015 and the DBT-JRF Junior Research Fellowship in 2014. 🏆🌟
Publications
Dr. Kumar has published extensively in renowned peer-reviewed journals. Some of his key publications include:
- Kumar P, Devaki B, Jonnala UK, et al. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation. Biochim Biophys Acta Mol Cell Res. 2020 Aug;1867(8):118728. DOI
- Kumar P, Siripini S, Sreedhar AS. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis. Cancer Rep (Hoboken). 2020 Aug; DOI
- Vykuntham NG, Kumar P, et al. Altered molecular pathways in breast cancer cells treated with Hsp90 inhibitors. Toxicol In Vitro. 2020 Jun; DOI
- Hong Z, Kumar P, et al. Targeting squalene epoxidase enhances radiotherapy efficacy. Cancer Res. 2022 Apr; DOI
- Kumar P, Schroder EA, Rajaram MVS, et al. The Battle of LPS Clearance in Host Defense. Cells. 2024; DOI
Conclusion
Dr. Pankaj Kumar is an outstanding candidate for the Research for Best Researcher Award due to his significant contributions to cancer biology and molecular mechanisms underlying drug resistance. His postdoctoral research, technical expertise, and numerous awards showcase his research excellence. With further diversification into immunology and greater international recognition, he would be an even more formidable candidate. Nevertheless, his current achievements alone make him highly deserving of consideration.